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Received March 12, 2013; accepted September 24, 2013AbstractBackground: Fabry disease is an X-linked inherited lysosomal storage disease that can be treated with the enzymes of agalsidase beta (Fab-
razyme) and agalsidase alfa (Replagal). Since June 2009, viral contamination of Genzyme’s production facility has resulted in a worldwide
shortage of agalsidase beta, leading to the switch to agalsidase alfa for patients with Fabry disease in Taiwan.
Methods: The medical records were retrospectively reviewed for nine male patients with Fabry disease from the start of agalsidase beta treatment
until the switch to agalsidase alfa for at least 1 year.
Results: After 12e112 months of enzyme replacement therapy (ERT), decreased plasma globotriaosylsphingosine (lyso-Gb3) was found in five
out of seven patients, indicating improvement in disease severity. Among the six patients with available echocardiographic data at baseline and
after ERT, all six experienced reductions of left ventricular mass index. Renal function, including microalbuminuria and estimated glomerular
filtration rate, showed stability after ERT. Mainz Severity Score Index scores revealed that all nine patients remained stable at 12 months after
switching to agalsidase alfa. ERT improved or stabilized cardiac status and stabilized renal function, while reducing plasma lyso-Gb3. ERT was
well tolerated, even among the three patients who had hypersensitivity reactions.
Conclusion: The switch of ERT from agalsidase beta to agalsidase alfa appears to be safe after 1 year of follow-up for Taiwanese patients with
Fabry disease.
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Fabry disease (MIM 301500) is an X-linked lysosomal
storage disorder caused by a deficient a-galactosidase A (a-
Gal A) activity, leading to progressive accumulation of glo-
botriaosylceramide (Gb3) and other neutral glycolipids in the
vascular endothelium of the skin, kidneys, heart, and brain. It
is a complex, multisystemic disorder characterized clinicallyhinese Medical Association. All rights reserved.
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opacities, gastrointestinal disturbances, progressive renal
impairment, cardiomyopathy, and cerebrovascular lesions.1
The onset of symptoms generally starts during childhood,
and by middle age, some degree of irreversible damage may
already have occurred. Life-threatening complications often
develop in untreated patients.2 The estimated incidence of
classic Fabry disease is one in 40,000e60,000 males in the
general population.1,3
During the past decade, there have been reports of late-
onset phenotypes of Fabry disease primarily involving the
heart,4e6 kidneys,7e9 or cerebrovascular system.10 Patients
with the cardiac variant lack the classic symptoms of Fabry
disease and present with left ventricular hypertrophy (LVH),
arrhythmias, or hypertrophic cardiomyopathy in the 5the8th
decades of life. Patients with the renal variant develop pro-
teinuria and may progress to end-stage renal disease, typically
after 50 years of age.
Prior to 2001, treatment of patients with Fabry disease was
exclusively supportive. The advancement of molecular genetic
techniques led to the development of enzyme replacement
therapy (ERT).11 There are two forms of ERT: agalsidase alfa
(Replagal; Shire Human Genetic Therapies, Lexington, MA,
USA) and agalsidase beta (Fabrazyme; Genzyme, Cambridge,
MA, USA). Previous studies showed that ERTwas an effective
treatment for neuropathic pain12 and could stabilize renal
function, or at least, slow the decline of renal function in many
patients with Fabry nephropathy13e20 and stabilize or improve
surrogate parameters such as cardiac size in those with
cardiomyopathy.16,21e24
Since June 2009, viral contamination of Genzyme’s pro-
duction facility has resulted in a worldwide shortage of agal-
sidase beta, leading to a switch to agalsidase alfa for patients
with Fabry disease in Taiwan. However, information is limited
regarding the clinical outcome of Fabry patients in whom the
treatment was switched from agalsidase beta to agalsidase
alfa.25e27 In this study, we retrospectively reviewed the clin-
ical findings of ERT in nine Taiwanese patients with Fabry
disease enrolled in the Fabry Outcome Survey who switched
from agalsidase beta to agalsidase alfa for at least 12 months.
Our aim was to evaluate the safety and effects on disease
stability for these patients under ERT as well as the effect of
the switch of treatment.
2. Methods2.1. Selection of participantsData from nine male patients with Fabry disease (three with
classic type, two with renal type, and four with cardiac type)
who received agalsidase beta treatment (1 mg/kg/biweekly)
initially and were then switched to agalsidase alfa (0.2 mg/kg/
biweekly) for at least 1 year between December 2002 and June
2012 in Taipei Veterans General Hospital, Taipei, Taiwan,
were retrospectively reviewed for this study. The patients’
ages when treatment began ranged widely, from 14.4 years to
66.7 years, and the duration of agalsidase beta therapy rangedfrom 0.7 months to 88.6 months. Informed written consent
was obtained from a parent for children and from patients
older than 18 years. The study was approved by the medical
ethics committee of Taipei Veterans General Hospital, Taiwan.2.2. Baseline and follow-up biochemical and clinical
evaluationAll patients had clinical manifestations of the disease, and
diagnosis was confirmed by plasma a-Gal A enzyme activity
assay and GLA gene mutation analysis.28,29 Prior to each
infusion, patients were premedicated with diphenhydramine
(0.5 mg/kg body weight). The data were collected retrospec-
tively prior to ERT and after the switch for at least 1 year,
including patient demographics, such as gender, age at diag-
nosis, height and body weight, and medical history. Further-
more, the relevant data pertaining to the left ventricular mass
(LVM), left ventricular mass index (LVMI), the thicknesses of
the intraventricular septum (IVS), and left posterior wall
(LPW) obtained by serial echocardiographic assessments,30e33
urine albumin-to-creatinine ratio (ACR), estimated glomerular
filtration rate (eGFR; based on serum creatinine concentra-
tion),34 plasma globotriaosylsphingosine (lyso-Gb3) concen-
tration,35,36 and severity of signs and symptoms of Fabry
disease using the Mainz Severity Score Index37 were recorded.
LVM was calculated according to the American Society of
Echocardiography simplified cubed equation. LVM was
indexed (LVMI) by height2.7 to normalize heart size to body
size. LVH was defined as an LVMI of 51 g/m2.7 in mal-
es.30e33 Adverse events were assessed by: history; physical
examination, including vital signs during treatment; patient
records of side effects; laboratory tests (chemistry, hematolo-
gy, urinalysis); and electrocardiography.2.3. Data analysisDescriptive statistics, including means, standard deviations,
and percentage change over time, were calculated. Changes in
LVMI, IVS, LPW, urine ACR, eGFR, and plasma lyso-Gb3
prior to and after treatment were analyzed using the Man-
neWhitney test. SPSS version 11.5 (SPSS Inc., Chicago, IL,
USA) was used, and differences were considered statistically
significant when p < 0.05.
3. Results3.1. DemographicsDetails of the nine patients’ backgrounds and clinical
characteristics are shown in Table 1. During the entire course
of ERT, only one patient (patient No. 5) underwent hemodi-
alysis and renal transplantation. The patient had been
receiving ERT with agalsidase beta since December 2002.
End-stage renal disease developed in 2004, and the patient
started to receive continuous ambulatory peritoneal dialysis
from October 2004. Because of infection of the catheter, the
patient started to undergo hemodialysis from September 2009.
Table 1
Baseline demographics of nine Taiwanese patients with Fabry disease who were switched from agalsidase beta to agalsidase alfa.
Patient No. 1 2 3 4 5 6 7 8 9
Type Classic Classic Classic Renal Renal Cardiac Cardiac Cardiac Cardiac
Sex M M M M M M M M M
Age at diagnosis (y) 14.2 33.0 49.4 30.7 34.7 42.7 53.3 62.6 65.4
Age at ERT (y) 14.4 33.0 49.4 31.3 35.4 42.8 53.4 63.4 66.7
GLA mutation W204X E398DfsX6 E398DfsX6 R112H R112H IVS4þ919G>A IVS4þ919G>A IVS4þ919G>A IVS4þ919G>A
Plasma a-Gal A enzyme activity
(nmol/h/mL)a
0 0.027 0.02 1.3 3.0 0.65 0.88 1.2 0.95
Plasma lyso-Gb3 (nM)b 178.4 54.95 71.48 1.48c 1.62d 4.44 5.19 3.49 7.8
Height (cm) 166 169 181 174 167 171 166 172 163
Body weight (kg) 78 63 64 90 75 94 65 78 59
Cardiac symptoms N N N Y Y Y Y Y Y
LVM (gm) 225.2 282.2 151.6 165.3e 232.1f 392.1 378.8 383.6 195.6
LVMI (g/m2.7) 57.3 68.5 30.5 37.1g 58h 92.1 76 88.7 52.3
IVS (mm) 10.1 13 10.5 10.5 11.2 16.7 14.6 19.4 15.4
LPW (mm) 11.7 11 7 7.5 8.2 12 15.2 13.3 8
Ejection fraction (%) 84 75 75 67 69 84 78 84 64
Fractional shortening (%) 54 44 44 37 39 53 46 53 34
Pacemaker N N N N N N N N N
Urine ACR (mg/mmol) 0.99 171.68 111.84 2.36 68.43 0.35 0.84 5.65 1.07
Serum creatinine (mg/dL) 0.8 1.12 2.33 1 3 0.8 0.84 0.83 0.65
eGFR (mL/min/1.73 m2) 133. 85.7 31.5 99.6 25.6 109.6 99.7 93.4 100.9
Hemodialysis N N N N Yi N N N N
Acroparesthesia Y Y Y N N N N N N
Angiokeratoma Y Y Y N N N N N N
Hypohydrosis N N Y N N N N N N
Cerebrovascular disorders N N N N N N Y N N
Dysacusis N Y Y Y N N N N N
Gastrointestinal symptoms N N Y Y N N N Y Y
Respiratory symptoms N N N Y N Y N N N
Agalsidase beta Start date 28 Aug 2009 15 Aug 2010 17 Nov 2010 20 Dec 2002 20 Dec 2002 6 Jan 2009 13 Dec 2008 1 May 2009 18 Aug 2009
Treatment (mo) 7 3.5 0.7 88.6 88.6 16.8 14.2 11.3 7.5
Adverse effects Y Y N N N N N N Y
Agalsidase alfa Start date 26 Mar 10 29 Nov 10 8 Dec 10 31 Mar 10 31 Mar 10 25 May 10 11 Feb 10 5 Apr 10 31 Mar 10
Treatment (mo) >12 >12 >12 >12 >12 >12 >12 >12 >12
Adverse effects N Y N N N N N N Y
ACR ¼ albumin-to-creatinine ratio; a-Gal A ¼ a-galactosidase A; eGFR ¼ estimated glomerular filtration rate; ERT ¼ enzyme replacement therapy; IVS ¼ intraventricular septum; LPW ¼ left posterior wall;
lyso-Gb3 ¼ globotriaosylsphingosine; LVM ¼ left ventricular mass; LVMI ¼ left ventricular mass index.
aReference range, 7.9e16.9.
bReference range < 0.01e0.5.
ceh These data were only available after enzyme replacement therapy for specific time intervals: c,d 108 months
eeh 100 months.
iPatient No. 5 had undergone hemodialysis since September 2009 and renal transplantation in November 2010.
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193H.-Y. Lin et al. / Journal of the Chinese Medical Association 77 (2014) 190e197The switch of ERT to agalsidase alfa was started in March
2010. The patient then underwent renal transplantation in
November 2010.3.2. Cardiac status, renal function, and lyso-Gb3
concentrationTable 2 shows the parameter changes in cardiac status,
renal function, and plasma lyso-Gb3 concentrations of these
nine patients after 12e112 months of ERT, comparing with the
baseline data prior to ERT. Among the six patients with
available echocardiographic data at baseline and after ERT, all
six experienced reductions of the LVMI (Fig. 1), six had
decreasing or stable thickness of the IVS, and four had
decreasing thickness of the LPW. For four patients with
microalbuminuria (urine ACR  2.0 mg/mmol for men)38
prior to ERT, three patients revealed improvement after ERT.
Among the eight patients with available data for eGFR, all
eight showed stable renal function after ERT (Fig. 2). Five of
seven patients had a decrease in plasma lyso-Gb3 concentra-
tion, indicating improvement in disease severity (Fig. 3).
However, because of the small sample size, there were noTable 2
Parameter changes in cardiac status, renal function, and plasma lyso-Gb3 before
disease.
Patient No. 1 2 3
Baseline LVMI (g/m2.7) 57.3 68.5 30.5
ERT duration (mo) 32 13 NA
LVMI after ERT 47.5 44.1 NA
LVMI change (%) 17 36 NA
p 0.073
Baseline IVS (mm) 10.1 13 10.5
ERT duration (mo) 32 13 NA
IVS after ERT 8.9 9.5 NA
IVS change (%) 12 27 NA
p 0.348
Baseline LPW (mm) 11.7 11 7
ERT duration (mo) 32 13 NA
LPW after ERT 8.9 10.6 NA
LPW change (%) 24 4 NA
p 0.228
Baseline urine ACR (mg/mmol) 0.99 171.68 111.84
ERT duration (mo) 27 18 18
Urine ACR after ERT 1.11 206.32 23.44
ACR change (%) 13 20 79
p 0.830
Baseline eGFR (ml/min/1.73 m2) 133.8 85.7 31.5
ERT duration (mo) 33 15 15
eGFR after ERT 141.2 83.1 31.6
eGFR change (%) 6 3 0
p 0.987
Baseline plasma lyso-Gb3 (nM) 178.4 54.95 71.48
ERT duration (mo) 27 16 12
Plasma lyso-Gb3 after ERT 75.64 45.13 58.80
Plasma lyso-Gb3 change (%) 58 18 18
p 0.524
ACR ¼ albumin-to-creatinine ratio; eGFR ¼ estimated glomerular filtration rate; ER
posterior wall; LVMI ¼ left ventricular mass index; lyso-Gb3 ¼ globotriaosylsphi
aed These data were only available after enzyme replacement therapy for specific
c,d 108 months.statistically significant differences after ERT for these six
parameters (p > 0.05).3.3. Mainz Severity Score IndexMainz Severity Score Index scores revealed that all nine
patients had mild-to-moderate Fabry disease (Mainz Severity
Score Index  40) at the preswitch baseline.37 The disease
remained stable at 12 months after switching to agalsidase
alfa, with mild improvements in cardiac or renal scores in
three patients (patients Nos. 6e8), and a slight deterioration in
general score in patient No. 9 (Table 3).3.4. Adverse eventsThree patients had hypersensitivity reactions (shortness of
breath, skin itching/urticaria, fever) at some point during their
treatment (Table 1).
3.4.1. Patient No. 1
Fever and chills were only noted at the time of first agal-
sidase beta infusion in August 2009. However, no adverseand after enzyme replacement therapy in nine Taiwanese patients with Fabry
4 5 6 7 8 9
37.1a 58b 92.1 76 88.7 52.3
NA NA 39 39 35 32
NA NA 63.4 50.4 77.7 51.1
NA NA 31 34 12 2
10.5 11.2 16.7 14.6 19.4 15.4
NA NA 39 29 35 21
NA NA 13.7 12.8 17.7 15.4
NA NA 18 12 10 0
7.5 8.2 12 15.2 13.3 8
NA NA 39 29 35 21
NA NA 12.2 11.7 8.2 10.6
NA NA 2 23 35 33
2.36 68.43 0.35 0.85 5.65 1.07
108 NA 41 39 37 34
1.89 NA 0.43 0.39 0.34 0.30
20 NA 23 54 94 72
99.6 25.6 109.6 99.7 93.4 100.9
112 NA 41 35 37 34
100.6 NA 115.1 92.5 89.7 98.4
1 NA 5 7 4 2
1.48c 1.62d 4.44 5.19 3.49 7.8
NA NA 30 35 31 12
NA NA 3.36 4.18 4.17 10.80
NA NA 24 19 19 38
T ¼ enzyme replacement therapy; IVS ¼ intraventricular septum; LPW ¼ left
ngosine; NA ¼ not available.
time intervals: a,b 100 months.
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Fig. 1. Left ventricular mass index (LVMI) versus treatment month for six patients with Fabry disease receiving enzyme replacement therapy for 13e39 months.
Arrowheads indicate the switch time of agalsidase beta to agalsidase alfa treatment for each patient.
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alfa treatment beginning March 2010.
3.4.2. Patient No. 2
Urticaria and dyspnea were seen after the fifth adminis-
tration of agalsidase beta. These symptoms improved with
intravenous antihistamine and steroids, and the reactions were
noted twice under agalsidase beta infusion after that. After
switching to agalsidase alfa treatment from November 2010,
adverse effects did not occur initially. However, after the 30th
instance of agalsidase alfa infusion, mild dyspnea was seen.
No reaction occurred after the 32nd administration of agalsi-
dase alfa.0
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Fig. 2. Individual estimated glomerular filtration rate (eGFR) values in eight patie
available) prior to being switched to agalsidase alfa treatment (months 0e26 if av3.4.3. Patient No. 9
Itching red plaques on the extensor aspects of all four limbs
and diarrhea were noted throughout both the whole courses of
agalsidase beta therapy and then after switching to agalsidase
alfa infusion. The symptoms were partially relieved following
oral antihistamines, topical steroids, and oral antidiarrheal
agents.
4. Discussion
This is the first report to demonstrate the efficacy of ERT
and the safety of switching from agalsidase beta to agalsidase
alfa in Taiwanese patients with Fabry disease. For most2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
nt (months)
Pt6 Pt7 Pt8 Pt9
nts with Fabry disease treated with agalsidase beta (from months 26 to 0 if
ailable).
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Fig. 3. Plasma globotriaosylsphingosine (lyso-Gb3) versus treatment month for seven patients with Fabry disease receiving enzyme replacement therapy for 12e35
months. Arrowheads indicate the switch time of agalsidase beta to agalsidase alfa treatment for each patient.
195H.-Y. Lin et al. / Journal of the Chinese Medical Association 77 (2014) 190e197patients in this study, ERT decreased plasma lyso-Gb3 con-
centration, stabilized or improved surrogate parameters (e.g.,
LVM) and the thicknesses of IVS and LPW in those with LVH,
improved microalbuminuria, and stabilized renal function in
those with Fabry nephropathy. Our results were consistent
with those of previous studies.13e24
In this study, we report data from nine male patients with
Fabry disease (three with classic type, two with renal type, and
four with cardiac type) who had received at least 12 months of
treatment with agalsidase alfa after switching from agalsidase
beta. Agalsidase alfa and agalsidase beta have several differ-
ences in structure, including glycosylation, sialylation, and
phosphorylation of mannose residues, which may cause dif-
ferences in tissue distribution and antibody production.
Moreover, agalsidase alfa and agalsidase beta are produced byTable 3
Mainz Severity Scores at the preswitch baseline and 12 months after switching fro
Patient No. Max score Score (baseline at switch)
General Neuro Cardio Renal
18 20 20 18
1 Classic 1 5 11 0
2 Classic 5 8 11 4
3 Classic 6 10 9 8
4 Renal 4 1 10 4
5 Renal 3 1 12 18
6 Cardiac 3 1 16 0
7 Cardiac 3 4 16 0
8 Cardiac 4 1 16 4
9 Cardiac 5 1 16 0
Mean 3.78 3.56 13.00 4.22
Cardio ¼ cardiovascular; Max ¼ maximum possible score; Neuro ¼ neurologicalexpression of the GLA gene in modified human cells derived
from fibroblasts and Chinese hamster ovary cells, respectively.
Patients are usually treated with the established protocol of
agalsidase alfa at 0.2 mg/kg and agalsidase beta at 1.0 mg/kg,
administered intravenously every 2 weeks. However, com-
parison between the two enzymes is difficult, mainly because
in the Phase III pivotal studies, evaluations of agalsidase alfa
and agalsidase beta were based predominantly on clinical and
histological primary end-points, respectively.12,39e41 Mean-
while, there have been few studies regarding the safety and
efficacy of ERT for patients who switched from one enzyme to
the other.25e27 Tsuboi and Yamamoto27 in Japan recently re-
ported findings involving 11 patients with Fabry disease who
switched from agalsidase beta to agalsidase alfa with standard
doses. They found that all patients maintained disease stabilitym agalsidase beta to agalsidase alfa in nine male patients with Fabry disease.
Score (12 mo)
Total General Neuro Cardio Renal Total
76 18 20 20 18 76
17 1 5 11 0 17
28 5 8 11 4 28
33 6 10 9 8 33
19 4 1 10 4 19
34 3 1 12 18 34
20 3 1 12 0 16
23 3 4 12 0 19
25 4 1 16 0 21
22 6 1 16 0 23
24.56 3.89 3.56 12.11 3.78 23.33
.
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months of follow-up, as evidenced by LVMI, eGFR, pain
scores, and quality-of-life indexes. In our study, besides the
improvement or stability of the parameters for the assessments
of cardiac status and renal function, Mainz Severity Score
Index scores also revealed the severity of signs and symptoms
of Fabry disease remained stable at 12 months after switching
to agalsidase alfa treatment. Our results were in accordance
with Tsuboi and Yamamoto’s.27
Beck et al16 reported a 20% reduction in LVM after 12
months of agalsidase alfa treatment with the standard dose (0.2
mg/kg/biweekly). Our study showed similar results, with an
average decrease of 22% in LVMI for six patients after ERT,
as well as 13% and 9% decrease in the thicknesses of IVS and
LPW, respectively. Schiffmann et al14 described stabilization
in patients with preserved renal function, but gradual deteri-
oration in advanced kidney disease following 4e4.5 years of
agalsidase alfa therapy. One patient in our study (patient No.
5) showed similarity to the latter outcome after ERT. However,
the other eight patients showed stable renal function, and three
of the four patients showed improvement of microalbuminuria
after treatment. Plasma lyso-Gb3 elevation is a hallmark of
Fabry disease and is associated with clinical manifesta-
tions.35,36 Thus, it was reasonable that the average baseline
plasma lyso-Gb3 concentration values of three classic patients
and four cardiac-type patients were 101.61 nM and 5.23 nM,
respectively (reference range < 0.01e0.5 nM). Five of seven
patients in our series showed an average reduction of 11% in
plasma lyso-Gb3 after at least 12 months of ERT, suggesting
improvement in disease severity.
Adverse events, such as pyrexia, dyspnea, and skin rash,
were reported in clinical trials of agalsidase beta and agalsi-
dase alfa treatments for Fabry disease. However, the frequency
and severity of adverse events diminish over time in most
patients due to infusion rate optimization, preinfusion medi-
cation, and, possibly, increased tolerance to the exogenous
protein because antibody titers often decline with time.13,14
Three and two of our patients had similar symptoms after
receiving agalsidase beta and agalsidase alfa treatment,
respectively, but the reactions were easily managed. None of
the three had serious sequelae, and all three were able to
continue with treatment. We were unable to measure the
immunoglobulin G antibodies against these two products, but
we assume that our patients’ reactions occurred by the same
mechanism.
This research had some limitations. As an uncontrolled
retrospective study, we could not compare the results of ERT
in our patients with those of any untreated control individuals.
Also, assessments for biochemical and clinical response were
not available at regular time intervals among these patients
during treatment. Thus, partial parameters of cardiac status
and renal function, and plasma lyso-Gb3 were not available at
the time point of the switch from agalsidase beta to agalsidase
alfa. Given this situation, the results of ERT shown in Table 2
could only represent the overall outcome of the previous
agalsidase beta and the later agalsidase alfa treatments.
Meanwhile, the results were reported after more than 12months of treatment. This period was not enough to display
some differences between the two enzymes, because Fabry
disease is a pleomorphic and long-lasting pathology and the
clinical outcome requires a long time to be evaluated. In
addition, the small sample size reflected the rare nature of this
genetic disorder, and the range of age at which treatment
began was wide, as was the degree of disease severity.
Therefore, studies in larger cohorts with a longer follow-up are
warranted. However, our experience reflects the problems that
clinicians are likely to encounter when treating patients with
Fabry disease, because each patient presents with a different
condition.
In conclusion, in our study of Taiwanese patients with
Fabry disease, ERT improved or stabilized cardiac status, and
stabilized renal function, while reducing the plasma lyso-Gb3
concentration. ERT was well tolerated, even among the three
patients who had hypersensitivity reactions. ERT for treatment
of Fabry disease has been endorsed by the National Health
Insurance program in Taiwan since April 2002. Our clinical
experience confirms that ERT is beneficial for Taiwanese pa-
tients with Fabry disease, just as it is in other populations. The
switch of ERT from agalsidase beta to agalsidase alfa appears
to be safe after 1 year of follow-up.
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